These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37217958)

  • 1. Post-neoadjuvant treatment pancreatic cancer resectability and outcome prediction using CT,
    Yoo J; Lee JM; Joo I; Lee DH; Yoon JH; Yu MH; Jang JY; Lee SH
    Cancer Imaging; 2023 May; 23(1):49. PubMed ID: 37217958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.
    Rayamajhi S; Balachandran A; Katz M; Reddy A; Rohren E; Bhosale P
    Abdom Radiol (NY); 2018 Feb; 43(2):505-513. PubMed ID: 28900703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and
    Jeong B; Oh M; Lee SS; Kim N; Kim JS; Lee W; Kim SC; Kim HJ; Kim JH; Byun JH
    Korean J Radiol; 2024 Jul; 25(7):644-655. PubMed ID: 38942458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional Value of Integrated
    Yoo J; Lee JM; Yoon JH; Joo I; Lee DH
    Korean J Radiol; 2021 May; 22(5):714-724. PubMed ID: 33660461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative Assessment of Pancreatic Cancer with FDG PET/MR Imaging versus FDG PET/CT Plus Contrast-enhanced Multidetector CT: A Prospective Preliminary Study.
    Joo I; Lee JM; Lee DH; Lee ES; Paeng JC; Lee SJ; Jang JY; Kim SW; Ryu JK; Lee KB
    Radiology; 2017 Jan; 282(1):149-159. PubMed ID: 27556273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival.
    Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH
    AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382
    [No Abstract]   [Full Text] [Related]  

  • 8. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Abdelrahman AM; Goenka AH; Alva-Ruiz R; Yonkus JA; Leiting JL; Graham RP; Merrell KW; Thiels CA; Hallemeier CL; Warner SG; Haddock MG; Grotz TE; Tran NH; Smoot RL; Ma WW; Cleary SP; McWilliams RR; Nagorney DM; Halfdanarson TR; Kendrick ML; Truty MJ
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1023-1032.e3. PubMed ID: 36075389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline Characteristics and Use of Pretherapeutic 18 F-Fluorodeoxyglucose-PET for Pancreatic Cancer.
    Carlson DM; Abdelrahman AM; Adjei Antwi SK; Tomlinson JL; Trivedi K; Karbhari A; Patnam Gopal Chetty N; Halfdanarson TR; Goenka AH; Truty MJ
    J Am Coll Surg; 2024 Jul; 239(1):9-17. PubMed ID: 38445645
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    García-Talavera P; Alejo E; Arias P; Verdú A; Tamayo P; Gómez-Caminero F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):207-213. PubMed ID: 34218882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of FIGO staging defined by combining MRI and [
    Raffa S; Lanfranchi F; Satragno C; Giannelli F; Marcenaro M; Coco A; Cena SE; Sofia L; Marini C; Mammoliti S; Levaggi A; Tagliafico AS; Sambuceti G; Barra S; Morbelli S; Belgioia L; Bauckneht M
    Curr Probl Cancer; 2023 Dec; 47(6):101007. PubMed ID: 37684197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
    Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
    Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.
    Santhosh S; Mittal BR; Bhasin DK; Rana SS; Gupta R; Das A; Nada R
    Ann Nucl Med; 2017 Oct; 31(8):575-581. PubMed ID: 28689356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.
    Kawanaka Y; Kitajima K; Fukushima K; Mouri M; Doi H; Oshima T; Niwa H; Kaibe N; Sasako M; Tomita T; Miwa H; Hirota S
    Eur J Radiol; 2016 May; 85(5):989-95. PubMed ID: 27130061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison Between Contrast-Enhanced Computed Tomography and Contrast-Enhanced Magnetic Resonance Imaging With Magnetic Resonance Cholangiopancreatography for Resectability Assessment in Extrahepatic Cholangiocarcinoma.
    Yoo J; Lee JM; Kang HJ; Bae JS; Jeon SK; Yoon JH
    Korean J Radiol; 2023 Oct; 24(10):983-995. PubMed ID: 37793669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer.
    de Jong TL; Koopman D; van der Worp CAJ; Stevens H; Vuijk FA; Vahrmeijer AL; Mieog JSD; de Groot JB; Meijssen MAC; Nieuwenhuijs VB; de Geus-Oei LF; Jager PL; Patijn GA
    Surg Oncol; 2023 Apr; 47():101909. PubMed ID: 36739788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.